Hong Kong Journal of Nephrology
Volume 9, Issue 1 , Pages 31-35 , April 2007

Combination Therapy of Angiotensin Converting Enzyme Inhibitor and Angiotensin AT1 Receptor Antagonist in Diabetic Nephropathy

References 

  1. Parving HH , Andersen AR , Smidt UM , Svendsen PA . Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy . Lancet . 1983;1:1175–1179
  2. The Diabetes Control and Complications Trial Research Group  . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus . N Engl J Med . 1993;329:977–986
  3. UK Prospective Diabetes Study (UKPDS) Group  . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) . Lancet . 1998;352:837–853
  4. UK Prospective Diabetes Study (UKPDS) Group  . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) . Lancet . 1998;352:854–865
  5. Schrier RW , Estacio RO , Jeffers B . Appropriate blood pressure control in NIDDM (ABCD) trial . Diabetologia . 1996;39:1646–1654
  6. Carey RM , Wang ZQ , Siragy HM . Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function . Hypertension . 2000;35:155–163
  7. Zafari AM , Ushio-Fukai M , Akers M , Yin Q , Shah A , Harrison DG , et al.   Role of NADH/NADPH oxidase-derived H 2O2 in angiotensin II-induced vascular hypertrophy . Hypertension . 1998;32:488–495
  8. Hostetter TH . Mechanisms of diabetic nephropathy . Am J Kidney Dis . 1994;23:188–192
  9. Lewis EJ , Hunsicker LG , Bain RP , Rohde RD . The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group . N Engl J Med . 1993;329:1456–1462
  10. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy . N Engl J Med . 2001;345:861–869
  11. Lewis EJ , Hunsicker LG , Clarke WR , Berl T , Pohl MA , Lewis JB , et al.   Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. The Collaborative Study Group . N Engl J Med . 2001;345:851–860
  12. Parving HH , Lehnert H , Brochner-Mortensen J , Gomis R , Andersen S , Arner P . Irbesartan in patients with type 2 diabetes and microalbuminuria study group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes . N Engl J Med . 2001;345:870–878
  13. Palmer BF . Renal dysfunction complicating the treatment of hypertension . N Engl J Med . 2002;347:1256–1261
  14. Katayama S , Kikkawa R , Isogai S , Sasaki N , Matsuura N , Tajima N , et al.   Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM) . Diabetes Res Clin Pract . 2002;55:113–121
  15. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors . J Clin Invest . 1997;99:1926–1935
  16. Viberti G , Wheeldon NM . Microalbuminuria reduction with valsartan (MARVAL) study investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect . Circulation . 2002;106:672–678
  17. Hebert LA , Falkenhain ME , Nahman NS , Cosio FG , O'Dorisio TM . Combination of ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy . Am J Nephrol . 1999;19:1–6
  18. Sterqiou GS , Skeva II , Baibas NM , Kalkana CB , Roussias LG , Mountokalakis TD . Does the antihypertensive response to angiotensin converting enzyme inhibition predict the anti-hypertensive response to angiotensin receptor antagonism? . Am J Hypertens . 2001;14:688–693
  19. Ruilope LM , Aldigier JC , Ponticelli C , Oddou-Stock P , Botteri F , Mann JF . Safety of the combination of valsartan and benazapril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease . J Hypertens . 2000;18:89–95
  20. Azizi M , Menard J . Combined blockade of the renin–angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists . Circulation . 2004;109:2492–2499
  21. Leehey DJ , Singh AK , Alavi N , Singh R . Role of angiotensin II in diabetic nephropathy . Kidney Int . 2000;77:S93–S98
  22. Manley HJ . Role of angiotensin-converting-enzyme inhibition in patients with renal disease . Am J Health Syst Pharm . 2000;57:S12–S18
  23. Fujisawa T, Ikegami H, Ono M, Nishino M, Noso S, Kawabata Y, et al. Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy . Am J Hypertens . 2005;18:13–17
  24. Song JH , Cha SH , Hong SB , Kim DH . Dual blockade of the renin– angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease . J Hypertens . 2006;24:S101–S106
  25. Matos JPS , de Lourdes Rodrigues M , Ismerim VL , Boasqueviscue EM , Genelhu V , Francischetti EA . Effects of dual blockade of the renin–angiotensin system in hypertensive type 2 diabetic patients with nephropathy . Clin Nephrol . 2005;64:180–189

PII: S1561-5413(07)60006-4

doi: 10.1016/S1561-5413(07)60006-4

Hong Kong Journal of Nephrology
Volume 9, Issue 1 , Pages 31-35 , April 2007

Article Tools